newsfilter
← Latest News
GlobeNewswire·

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1) of $164.6